Revumenib Earns FDA Priority Review in R/R KMT2Ar Acute Leukemia
Revumenib, a first-in-class Menin inhibitor, was granted priority review from the FDA for the treatment of adult and pediatric relapsed or refractory KMT2A-rearranged acute leukemia.
Revumenib, a first-in-class Menin inhibitor, was granted priority review from the FDA for the treatment of adult and pediatric relapsed or refractory KMT2A-rearranged acute leukemia.
Fred Hutch Obliteride is a bike ride and 5K that empowers people to help cure cancer faster by raising funds for Fred Hutchinson Cancer Center.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Fred Hutch Obliteride is a bike ride and 5K that empowers people to help cure cancer faster by raising funds for Fred Hutchinson Cancer Center.
Prolonged administration of imatinib maintenance therapy for 6 years improved disease-free survival in patients with gastrointestinal stromal tumors.
Compared with ruxolitinib, momelotinib improved mild, moderate, and severe anemia in patients with myelofibrosis who were naive to JAK inhibitors, according to the phase 3…
Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
Head and Neck Microvascular Reconstructive Workshop *BRAND NEW COURSE! Tuesday, May 14, 2024 at the Hyatt Regency Chicago Explore vital harvesting techniques for a…
Valerae Lewis, M.D., is a leader in the field of orthopedic oncology and chairs MD Anderson’s Orthopaedic Oncology department. Here, she shares what led her…
An abstract is unavailable.
Fuzuloparib with or without apatinib provided superior PFS benefit vs chemotherapy in HER2– metastatic breast cancer harboring germline BRCA1/2 mutations.